Description | The anti-BDNF R3BH1 antibody has been developed to specifically target human BDNF and inhibit its interaction with the TrkB receptor, demonstrating an IC₅₀ range of 0.1-0.5 nM. The immunogen utilized for the development of this molecule involved the immunization of chickens with a mixture of human BDNF. |
Clonality | Monoclonal |
Host Species | Human |
Target Species | Human |
Immunogen | A mixture of human BDNF. |
Epitope | C-terminus |
IC50 | 0.1-0.5 nM |
Affinity | KD = 34 ± 5 nM |
Isotype | Human IgG1, lambda |
Expression Species | HEK293F or CHO |
Conjugation | None |
Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
Endotoxin | <1 EU/mg |
Purification | Protein A affinity purified |
Sterility | 0.2 μM filtered |
Formulation | PBS, pH 7.4 |
Preservation | No preservatives |
Stabilizer | No stabilizers |
Storage | Store at 4°C within a week. For longer storage, aliquot and store at -20°C. |
Application | Inhib; ELISA; Neut; FC |
ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
WB | Western Blot Protocol |
FC | Flow Cytometry Protocol |
Target | BDNF |
Alternative Name | Brain Derived Neurotrophic Factor; Neurotrophin; Abrineurin; Brain-Derived Neurotrophic Factor; ANON2; BULN2 |
Gene ID | 627 |
UniProt | P23560 |
Related pathway | Apoptotic Pathways in Synovial Fibroblasts and Downstream signaling of activated FGFR2 |
Research Area | Signal Pathway |
Related Disease | Parkinson's disease |